Clinical Trials Logo
  1. Home
  2. Severe Combined Immunodeficiency
  3. NCT01420627

EZN-2279 in Patients With ADA-SCID

Severe Combined Immunodeficiency Clinical Trial

Official title:
A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency

Clinical Trial Summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01420627
Study type Interventional
Source Leadiant Biosciences, Inc.
Contact
Status Completed
Phase Phase 3
Start date January 24, 2014
Completion date May 29, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT00006335 - Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID N/A
Not yet recruiting NCT02231983 - Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China N/A
Active, not recruiting NCT03597594 - Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Phase 1/Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00001255 - Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study N/A
Recruiting NCT05651113 - The Experience of Screening for SCID
Completed NCT00794508 - MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Phase 2
Recruiting NCT03538899 - Autologous Gene Therapy for Artemis-Deficient SCID Phase 1/Phase 2
Recruiting NCT05298930 - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00845416 - Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Completed NCT03878069 - Registry Study of Revcovi Treatment in Patients With ADA-SCID
Recruiting NCT01019876 - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Phase 2/Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Withdrawn NCT02177760 - Sirolimus Prophylaxis for aGVHD in TME SCID Phase 2
Recruiting NCT00695279 - Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Terminated NCT02127892 - SCID Bu/Flu/ATG Study With T Cell Depletion Phase 1/Phase 2
Completed NCT04246840 - Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft
Completed NCT01529827 - Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2